<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e9022492-18a7-44e1-9a89-45a4c06c72f1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Mono-Linyah safely and effectively. See full prescribing information for Mono-Linyah. Mono-Linyah (norgestimate/ethinyl estradiol) tablets, for oral use Initial U.S. Approval:1989</title>
   <effectiveTime value="20250120"/>
   <setId root="84a20017-344b-4684-a915-c85a55fcbbcb"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="830546433" root="1.3.6.1.4.1.519.1"/>
            <name>Northstar Rx LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="527695995" root="1.3.6.1.4.1.519.1"/>
                  <name>Novast Laboratories, Ltd.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="527695995" root="1.3.6.1.4.1.519.1"/>
                        <name>Novast Laboratories, Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="16714-360" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="label"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="16714-360" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="16714-360" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pack"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="16714-360" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="7f185610-5ec1-41af-9a72-4c1e92f332b7"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250120"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="16714-360" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Mono-Linyah
								</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>norgestimate and ethinyl estradiol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="16714-360-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43199" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKET"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20120523"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="16714-360-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20120523"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="3" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="16714-360-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20120523"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="6" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="16714-360-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20120523"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="21" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Mono-Linyah
										</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>norgestimate and ethinyl estradiol</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="0.25" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="C291HFX4DY" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NORGESTIMATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="C291HFX4DY" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>NORGESTIMATE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="0.035" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETHINYL ESTRADIOL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ETHINYL ESTRADIOL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 2</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 1</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C RED NO. 40</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>D&amp;C YELLOW NO. 10</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYVINYL ALCOHOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TALC</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="1DI56QDM62" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LECITHIN, SOYBEAN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>STARCH, PREGELATINIZED CORN</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA090523" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20120523"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                                    <originalText>biconvex</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="PQ" value="5" unit="mm"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="INT" value="1"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">C3</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="7" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Inert
										</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name> placebo </name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="VH2XOU12IE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYDEXTROSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSES</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIACETIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>STARCH, PREGELATINIZED CORN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 8000</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA090523" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20120523"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                                    <originalText>biconvex</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="PQ" value="5" unit="mm"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="INT" value="1"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">P;N</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA090523" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20120523"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID969">
               <id root="41a12f6c-6bd5-44aa-b933-ffe720201d0e"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20241126"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID971">Contraindications, Pregnancy (<linkHtml href="#ID1007">4</linkHtml>) Removed 06/2023</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID972">
               <id root="6e36fcbe-0084-4ab8-8707-d597b186c39c"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS</title>
               <effectiveTime value="20250120"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID974">
                           <content styleCode="bold">WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>● <content styleCode="bold">Mono-Linyah is contraindicated in </content>
                           <content styleCode="bold">women over 35 years old who smoke. <linkHtml href="#ID1007">(4)</linkHtml>
                           </content>
                        </paragraph>
                        <paragraph>● <content styleCode="bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral </content>
                           <content styleCode="bold">contraceptives (COC) use. <linkHtml href="#ID1007">(4)</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID975">
                     <id root="9464300e-0a02-48ea-b41a-55549e86a463"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID976">
                           <content styleCode="bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke <content styleCode="italics">[see <linkHtml href="#ID1007">Contraindications (4)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240326"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID977">
               <id root="e12aeaad-0f1b-4ae9-bdf0-18257dedfa87"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20241125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID979">Mono-Linyah is a combination of norgestimate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. (<linkHtml href="#ID980">1.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID980">
                     <id root="cae9d0ff-6397-4f74-a845-4af069cfca20"/>
                     <title>1.1 Oral Contraceptive</title>
                     <text>
                        <paragraph ID="ID981">Mono-Linyah tablets are indicated for use by females of reproductive potential to prevent pregnancy <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID1106">14</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID982">
               <id root="091ee309-f132-450a-b12f-73788372bec1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250120"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID984" styleCode="Disc">
                           <item>Take one tablet daily by mouth at the same time every day <linkHtml href="#ID987">(2.1)</linkHtml>
                           </item>
                           <item>Take tablets in the order directed on the blister pack <linkHtml href="#ID987">(2.1)</linkHtml>
                           </item>
                           <item>Do not skip or delay tablet intake. <linkHtml href="#ID987">(2.1)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID987">
                     <id root="20cce554-6b3b-44e5-91a1-50210f50a4fc"/>
                     <title>2.1 Recommended Dosage and Administration</title>
                     <text>
                        <paragraph>Take one tablet by mouth at the same time each day with or without food. Table 1 provides the recommended dosage and administration instructions for Mono-Linyah.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="Lad8b962a-4c0d-456a-b5d6-d6a389a221d4"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Starting Mono-Linyah after Abortion or Miscarriage</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">First-trimester</content>
                        </paragraph>
                        <list listType="unordered" ID="ID990" styleCode="Disc">
                           <item>After a first-trimester abortion or miscarriage, Mono-Linyah may be started immediately. An additional method of contraception is not needed if Mono-Linyah is started immediately.</item>
                           <item>If Mono-Linyah is not started within 5 days after termination of the pregnancy, the patient should use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of her first cycle pack of Mono-Linyah.</item>
                        </list>
                        <paragraph ID="ID991">
                           <content styleCode="italics">Second-trimester</content>
                        </paragraph>
                        <list listType="unordered" ID="ID992" styleCode="Disc">
                           <item>Do not start until 4 weeks after a second-trimester abortion or miscarriage, due to the increased risk of thromboembolic disease. Start Mono-Linyah, following the instructions in Table 1 for Day 1 or Sunday start, as desired. If using Sunday start, use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of the patient's first cycle pack of Mono-Linyah.<content styleCode="italics">[see Contraindications (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#ID1007">4</linkHtml>
                              </content>
                              <content styleCode="italics">) and Warnings and Precautions (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#ID1016">5.1</linkHtml>
                              </content>
                              <content styleCode="italics">)].</content>
                           </item>
                        </list>
                        <paragraph ID="ID993">
                           <content styleCode="underline">Starting Mono-Linyah after Childbirth</content>
                        </paragraph>
                        <list listType="unordered" ID="ID994" styleCode="Disc">
                           <item>Do not start until 4 weeks after delivery, due to the increased risk of thromboembolic disease. Start contraceptive therapy with Mono-Linyah following the instructions in Table 1 for women not currently using hormonal contraception.</item>
                           <item>Mono-Linyah is not recommended for use in lactating women<content styleCode="italics">[see Use in Specific Populations (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#ID1078">8.2</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content> .</item>
                           <item>If the woman has not yet had a period postpartum, consider the possibility of ovulation and conception occurring prior to use of Mono-Linyah.<content styleCode="italics">[see Contraindications (</content>
                              <linkHtml href="#ID1007">4</linkHtml>
                              <content styleCode="italics">), Warnings and Precautions (</content>
                              <linkHtml href="#ID1016">5.1</linkHtml>
                              <content styleCode="italics">), and Use in Specific Populations (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#ID1076">8.1</linkHtml> and <linkHtml href="#ID1078">8.2</linkHtml>
                              </content>
                              <content styleCode="italics">)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID996">
                     <id root="d0c9894c-418a-4dce-b601-36dcca822a24"/>
                     <title>2.2 Recommendations Regarding Missed Doses</title>
                     <text>
                        <paragraph>Contraceptive failure may occur when active tablets are missed. Table 2 describes instructions for Mono-Linyah dosing and use of additional non-hormonal contraception (such as condoms) when active tablets are missed.<renderMultiMedia referencedObject="L280e0530-bc23-4b4a-a6c5-a5f656c4b8c6"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID998">
                     <id root="4a094b32-58ed-4a7b-a79a-6d202d17b6e6"/>
                     <title>2.3 Dosage Recommendations if Vomiting or Diarrhea Occurs</title>
                     <text>
                        <paragraph ID="ID999">In case of severe vomiting or diarrhea, absorption may not be complete and additional contraceptive measures should be taken. If vomiting or diarrhea occurs within 3 to 4 hours after taking an active tablet, handle this as a missed tablet.<content styleCode="italics"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="Lad8b962a-4c0d-456a-b5d6-d6a389a221d4">
                     <text>table1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="table1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L280e0530-bc23-4b4a-a6c5-a5f656c4b8c6">
                     <text>table2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="table2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1000">
               <id root="1e15f2ce-2ab5-4dbe-895f-1bdc40bc43a9"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20240331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID1002">Mono-Linyah consists of 28 round, biconvex, coated tablets in the following order <linkHtml href="#ID1000">(3)</linkHtml>:</paragraph>
                        <list listType="unordered" ID="ID1003" styleCode="Disc">
                           <item>21 blue tablets each containing 0.250 mg norgestimate and 0.035 mg ethinyl estradiol</item>
                           <item>7 white tablets (inert)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID1004">
                     <id root="a0569f66-22b1-4927-a2e3-d2ef00fd6402"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID1005">Mono-Linyah Tablets are available in blister cards. Each blister card contains 28 tablets in the following order:</paragraph>
                        <list listType="unordered" ID="ID1006" styleCode="Disc">
                           <item>21 blue, round, biconvex, coated tablet imprinted "C3" on one side of the tablet and contains 0.250 mg norgestimate and 0.035 mg ethinyl estradiol</item>
                           <item>7 white, round, biconvex tablets (non-hormonal placebo) imprinted "P" on one side and "<content styleCode="underline">N</content>" on the other side contains inert ingredients</item>
                        </list>
                     </text>
                     <effectiveTime value="20240331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1007">
               <id root="f6f6cc1b-3159-476e-803f-9f7bcc71af2b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20250120"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID1009" styleCode="Disc">
                           <item>A high risk of arterial or venous thrombotic diseases <linkHtml href="#ID1007">(4)</linkHtml>
                           </item>
                           <item>Liver tumors or liver disease <linkHtml href="#ID1007">(4)</linkHtml>
                           </item>
                           <item>Undiagnosed abnormal uterine bleeding <linkHtml href="#ID1007">(4)</linkHtml>
                           </item>
                           <item>Breast cancer <linkHtml href="#ID1007">(4)</linkHtml>
                           </item>
                           <item>Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (<linkHtml href="#ID1007">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID1010">
                     <id root="bdbd8fde-50c2-4eef-a77e-92d7d6bab520"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID1011">Mono-Linyah is contraindicated in females who are known to have or develop the following conditions:</paragraph>
                        <list listType="unordered" ID="ID1012" styleCode="Disc">
                           <item>A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:<list listType="unordered" styleCode="Circle">
                                 <item>Smoke, if over age 35<content styleCode="italics">[see Boxed Warning and Warnings and Precautions (<linkHtml href="#ID1016">5.1</linkHtml>)]</content>
                                 </item>
                                 <item>Have deep vein thrombosis or pulmonary embolism, now or in the past<content styleCode="italics">[see Warnings</content> and Precautions <content styleCode="italics">
                                       <linkHtml href="#ID1016">(5.1)</linkHtml>
                                    </content>
                                    <content styleCode="italics">]</content>
                                 </item>
                                 <item>Have inherited or acquired hypercoagulopathies<content styleCode="italics">[see Warnings and Precautions</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#ID1016">(5.1)</linkHtml>
                                    </content>
                                    <content styleCode="italics">]</content>
                                 </item>
                                 <item>Have cerebrovascular disease<content styleCode="italics">[see Warnings and Precautions</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#ID1016">(5.1)</linkHtml>
                                    </content>
                                    <content styleCode="italics">]</content>
                                 </item>
                                 <item>Have coronary artery disease<content styleCode="italics">[see Warnings and Precautions</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#ID1016">(5.1)</linkHtml>]</content>
                                 </item>
                                 <item>Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)<content styleCode="italics">[see Warnings and Precautions</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#ID1016">(5.1)</linkHtml>]</content>
                                 </item>
                                 <item>Have uncontrolled hypertension<content styleCode="italics">[see Warnings and Precautions <linkHtml href="#ID1022">(5.4)</linkHtml>]</content>
                                 </item>
                                 <item>Have diabetes mellitus with vascular disease<content styleCode="italics">[see Warnings and Precautions <linkHtml href="#ID1026">(5.6)</linkHtml>]</content>
                                 </item>
                                 <item>Have headaches with focal neurological symptoms or migraine headaches with aura<content styleCode="italics">[see Warnings and Precautions <linkHtml href="#ID1028">(5.7)</linkHtml>]</content>
                                 </item>
                              </list>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>Women over age 35 with any migraine headaches<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#ID1028">5.7</linkHtml>)]</content>
                           </item>
                           <item>Liver tumors, benign or malignant, or liver disease<content styleCode="italics">[see Warnings and Precautions <linkHtml href="#ID1018">(5.2)</linkHtml>]</content>
                           </item>
                           <item>Undiagnosed abnormal uterine bleeding<content styleCode="italics">[see Warnings and Precautions <linkHtml href="#ID1030">(5.8)</linkHtml>]</content>
                           </item>
                           <item>Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive<content styleCode="italics">[</content>
                              <content styleCode="italics">see Warnings and Precautions <linkHtml href="#ID1036">(5.10)</linkHtml>
                              </content>
                              <content styleCode="italics">]</content>
                           </item>
                           <item>Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations<content styleCode="italics">[see Warnings and Precautions</content>
                              <content styleCode="italics">
                                 <linkHtml href="#ID1020">(5.3)</linkHtml>]</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250120"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1013">
               <id root="5cd3bf3d-4dd4-441c-b6e4-97c9858e5224"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250120"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID1015" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Thromboembolic Disorders and Other Vascular Problems:</content> Stop Mono-Linyah if a thrombotic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. (<linkHtml href="#ID1016">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Liver disease:</content> Discontinue Mono-Linyah if jaundice occurs. (<linkHtml href="#ID1018">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">High blood pressure:</content> If used in women with well-controlled hypertension, monitor blood pressure and stop Mono-Linyah if blood pressure rises significantly. (<linkHtml href="#ID1022">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Carbohydrate and lipid metabolic effects:</content> Monitor prediabetic and diabetic women taking Mono-Linyah. Consider an alternate contraceptive method for women with uncontrolled dyslipidemia. (<linkHtml href="#ID1026">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Headache:</content> Evaluate significant change in headaches and discontinue Mono-Linyah if indicated. (<linkHtml href="#ID1028">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Bleeding Irregularities and Amenorrhea:</content> Evaluate irregular bleeding or amenorrhea. (<linkHtml href="#ID1030">5.8</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID1016">
                     <id root="be03019b-dd38-4c4a-8445-19ecc7b6421c"/>
                     <title>5.1 Thromboembolic Disorders and Other Vascular Problems</title>
                     <text>
                        <list listType="unordered" ID="ID1017" styleCode="Disc">
                           <item>Stop Mono-Linyah if an arterial thrombotic event or venous thromboembolic (VTE) event occurs.</item>
                           <item>Stop Mono-Linyah if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately<content styleCode="italics"> [see Adverse Reactions (</content>
                              <linkHtml href="#ID1058">6.2</linkHtml>
                              <content styleCode="italics">)]</content> .</item>
                           <item>If feasible, stop Mono-Linyah at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during and following prolonged immobilization.</item>
                           <item>Start Mono-Linyah no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.</item>
                           <item>The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 cases per 10,000 woman-years. The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued.</item>
                           <item>Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). This risk increases with age, particularly in women over 35 years of age who smoke.</item>
                           <item>Use COCs with caution in women with cardiovascular disease risk factors.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1018">
                     <id root="cd1bd4fe-590e-4910-9253-873607e39137"/>
                     <title>5.2 Liver Disease</title>
                     <text>
                        <paragraph ID="ID1019">
                           <content styleCode="underline">Impaired Liver Function</content>
                        </paragraph>
                        <paragraph>Mono-Linyah is contraindicated in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver <content styleCode="italics">[</content>
                           <content styleCode="italics">see Contraindications <linkHtml href="#ID1007">(4)</linkHtml>]. </content>
                           <content>Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Mono-Linyah if jaundice develops.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Liver Tumors</content>
                        </paragraph>
                        <paragraph>Mono-Linyah is contraindicated in women with benign and malignant liver tumors <content styleCode="italics">[see Contraindications <linkHtml href="#ID1007">(4)</linkHtml>]. </content>Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.</paragraph>
                        <paragraph>Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (&gt;8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1020">
                     <id root="35657f9e-05c1-462c-ba6a-567f3a98ddc6"/>
                     <title>5.3 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment</title>
                     <text>
                        <paragraph ID="ID1021">During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs. Discontinue Mono-Linyah prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir <content styleCode="italics">[see Contraindications (</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID1007">4</linkHtml>)]</content>. Mono-Linyah can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1022">
                     <id root="95195f9d-d9eb-479c-8e4c-dfd354baa938"/>
                     <title>5.4 High Blood Pressure</title>
                     <text>
                        <paragraph ID="ID1023">Mono-Linyah is contraindicated in women with uncontrolled hypertension or hypertension with vascular disease <content styleCode="italics">[see Contraindications <linkHtml href="#ID1007">(4)</linkHtml>]</content>. For women with well- controlled hypertension, monitor blood pressure and stop Mono-Linyah if blood pressure rises significantly.</paragraph>
                        <paragraph>An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. The incidence of hypertension increases with increasing concentrations of progestin.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1024">
                     <id root="e4e043c3-86bf-4742-b04c-66a19dd1ed2a"/>
                     <title>5.5 Gallbladder Disease</title>
                     <text>
                        <paragraph ID="ID1025">Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Women with a history of pregnancy-related cholestasis may be at an increased risk for COC related cholestasis.</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1026">
                     <id root="670bc263-5a84-4db7-8773-b599ada9848e"/>
                     <title>5.6 Carbohydrate and Lipid Metabolic Effects</title>
                     <text>
                        <paragraph ID="ID1027">Carefully monitor prediabetic and diabetic women who take Mono-Linyah. COCs may decrease glucose tolerance.</paragraph>
                        <paragraph>Consider alternative contraception for women with uncontrolled dyslipidemias. A small proportion of women will have adverse lipid changes while on COCs.</paragraph>
                        <paragraph>Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1028">
                     <id root="2c2bb02f-4780-4ac8-93f7-354637fb865e"/>
                     <title>5.7 Headache</title>
                     <text>
                        <paragraph ID="ID1029">If a woman taking Mono-Linyah develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue Mono-Linyah if indicated.</paragraph>
                        <paragraph>Consider discontinuation of Mono-Linyah in the case of increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event).</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1030">
                     <id root="f852ab9c-b612-4941-a490-eba3c7fb8f58"/>
                     <title>5.8 Bleeding Irregularities and Amenorrhea</title>
                     <text>
                        <paragraph ID="ID1031">
                           <content styleCode="underline">Unscheduled Bleeding and Spotting</content>
                        </paragraph>
                        <paragraph>Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different contraceptive product.</paragraph>
                        <paragraph>In clinical trials of norgestimate and ethinyl estradiol Tablets 0.25mg/0.035mg, the frequency and duration of breakthrough bleeding and/or spotting was assessed in 1,647 patients (21,275 evaluable cycles) and 4,826 patients (35,546 evaluable cycles), respectively. A total of 100 (7.5%) women discontinued norgestimate and ethinyl estradiol Tablets 0.25mg/0.035mg, at least in part, due to bleeding or spotting. Based on data from the clinical trials, 14-34% of women using norgestimate and ethinyl estradiol Tablets 0.25mg/0.035mg experienced unscheduled bleeding per cycle in the first year. The percent of women who experienced breakthrough/unscheduled bleeding tended to decrease over time.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Amenorrhea and Oligomenorrhea</content>
                        </paragraph>
                        <paragraph>Women who use Mono-Linyah may experience amenorrhea. Some women may experience amenorrhea or oligomenorrhea after discontinuation of COCs, especially when such a condition was pre-existent.</paragraph>
                        <paragraph>If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1034">
                     <id root="0aa8073e-0264-46ec-b750-e86894abd92e"/>
                     <title>5.9 Depression</title>
                     <text>
                        <paragraph ID="ID1035">Carefully observe women with a history of depression and discontinue Mono-Linyah if depression recurs to a serious degree.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1036">
                     <id root="beb8485a-d8dc-4fde-82df-84b730a16bd2"/>
                     <title>5.10 Malignant Neoplasms</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Breast Cancer</content>
                        </paragraph>
                        <paragraph>Mono-Linyah is contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive <content styleCode="italics">[see <linkHtml href="#ID1007">Contraindications (4)</linkHtml>].</content>
                           <br/>Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (&lt;6 months since last use) and current users with longer duration of COC use<content styleCode="italics"> [see <linkHtml href="#ID1058">Postmarketing Experience (6.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cervical Cancer</content>
                        </paragraph>
                        <paragraph>Some studies suggest that COC use has been associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1040">
                     <id root="80c9e709-16d1-4f04-88a4-b6b540d2f148"/>
                     <title>5.11 Effect on Binding Globulins</title>
                     <text>
                        <paragraph ID="ID1041">The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin. The dose of replacement thyroid hormone or cortisol therapy may need to be increased.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1042">
                     <id root="cb3d63c1-9190-4697-9b67-ccca1d5d47aa"/>
                     <title>5.12 Monitoring</title>
                     <text>
                        <paragraph ID="ID1043">A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1044">
                     <id root="40db9905-4389-41d7-b4f6-6e08059ef267"/>
                     <title>5.13 Hereditary Angioedema</title>
                     <text>
                        <paragraph ID="ID1045">In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1046">
                     <id root="272ae2ec-2631-4ecb-9c82-8c3064cb2905"/>
                     <title>5.14 Chloasma</title>
                     <text>
                        <paragraph ID="ID1047">Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking Mono-Linyah.</paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1048">
               <id root="1633daae-c7e2-440e-ae5d-b0df80f167a4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250120"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID1050">The most common adverse reactions reported during clinical trials (≥2%) were: headache/migraine, abdominal/gastrointestinal pain, vaginal infection, genital discharge, breast issues (including breast pain, discharge, and enlargement), mood disorders (including depression and mood altered), flatulence, nervousness, rash. (<linkHtml href="#ID1056">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID1051">
                     <id root="5d2f77a0-786e-4c16-a4f0-3f3f9c88b971"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID1052">The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:</paragraph>
                        <list listType="unordered" ID="ID1053" styleCode="Disc">
                           <item>Serious cardiovascular events and stroke<content styleCode="italics"> [</content>
                              <content styleCode="italics">see <linkHtml href="#ID972">Boxed Warning</linkHtml> and Warnings and Precautions <linkHtml href="#ID1016">(5.1)</linkHtml>
                              </content>
                              <content styleCode="italics">]</content>
                           </item>
                           <item>Vascular events<content styleCode="italics"> [</content>
                              <content styleCode="italics">see Warnings and Precautions <linkHtml href="#ID1016">(5.1)</linkHtml>
                              </content>
                              <content styleCode="italics">]</content>
                           </item>
                           <item>Liver disease <content styleCode="italics">[</content>
                              <content styleCode="italics">see Warnings and Precautions <linkHtml href="#ID1018">(5.2)</linkHtml>
                              </content>
                              <content styleCode="italics">]</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1056">
                     <id root="0efdaac3-dde9-4654-8d35-dac2ad9ae176"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph ID="ID1057">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The safety of norgestimate and ethinyl estradiol 0.25mg/0.035mg tablets was evaluated in 1,647 healthy women of child-bearing potential who participated in 3 clinical trials and received at least 1 dose of norgestimate and ethinyl estradiol 0.25mg/0.035mg tablets for contraception. Two trials were randomized active-controlled trials and 1 was an uncontrolled open-label trial. In all 3 trials, subjects were followed for up to 24 cycles.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Common Adverse Reactions (≥2% of subjects)</content>: The most common adverse reactions reported  by at least 2% of the 1,647 women were the following in order of decreasing incidence: headache/migraine (32.9%), abdominal/gastrointestinal pain (7.8%), vaginal infection (8.4%), genital discharge (6.8%), breast issues (including breast pain, discharge,and enlargement) (6.3%), mood disorders (including depression and mood altered) (5.0%), flatulence (3.2%), nervousness (2.9%), and rash (2.6%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Leading to Study Discontinuation</content>: Over the three trials, between 11 to 21% of subjects discontinued the trial due to an adverse reaction. The most common adverse reactions (≥1%) leading to discontinuation were: metrorrhagia (6.9%), nausea/vomiting (5.0%), headache (4.1%), mood disorders (including depression and mood altered) (2.4%), premenstrual syndrome (1.7%),  hypertension  (1.4%),  breast  pain  (1.4%),  nervousness  (1.3%),  amenorrhea  (1.1%), dysmenorrhea (1.1%), weight increased (1.1%), and flatulence (1.1%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Serious Adverse Reactions</content>: breast cancer (1 subject), mood disorders including depression, irritability, and mood swings (1 subject), myocardial infarction (1 subject), and venous thromboembolic events including pulmonary embolism (1 subject) and deep vein thrombosis (DVT) (1 subject).</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1058">
                     <id root="11644716-e413-49c2-8495-c14e474fbbcc"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 1).</paragraph>
                        <paragraph>Three studies compared breast cancer risk between current or recent COC users (&lt;6 months since last use) and never users of COCs (Figure 1). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1: Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="L1bb37679-579d-4429-815b-2bdb36d3dbfc"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">RR</content> = relative risk; <content styleCode="bold">OR</content> = odds ratio; <content styleCode="bold">HR</content> = hazard ratio. “<content styleCode="bold">ever COC</content>” are females with current or past COC use; “<content styleCode="bold">never COC</content>
                           <content styleCode="bold">use</content>” are females that never used COCs.</paragraph>
                        <paragraph/>
                        <paragraph>The following additional adverse drug reactions have been reported from worldwide postmarketing experience with norgestimate/ethinyl estradiol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and Infestations</content>: Urinary tract infection;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Neoplasms Benign, Malignant and Unspecified (Incl. Cysts and Polyps)</content>: Breast cancer, benign breast neoplasm, hepatic adenoma, focal nodular hyperplasia, breast cyst;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders</content>: Anaphylactic reaction, hypersensitivity;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Nutrition Disorders</content>: Dyslipidemia;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders</content>: Anxiety, insomnia;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders</content>: Syncope, convulsion, paresthesia, dizziness;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders</content>: Visual impairment, dry eye, contact lens intolerance;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ear and Labyrinth Disorders</content>: Vertigo;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders</content>: Tachycardia, palpitations;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Events</content>: Deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, hot flush, venous thrombosis (including Budd Chiari Syndrome and hepatic vein thrombosis);</paragraph>
                        <paragraph>
                           <content styleCode="italics">Arterial Events: </content>Arterial thromboembolism, myocardial infarction, cerebrovascular accident;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders</content>: Dyspnea;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders</content>: Pancreatitis, abdominal distension, diarrhea, constipation;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary Disorders: </content>Hepatitis;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders</content>: Angioedema, erythema nodosum, hirsutism, night sweats, hyperhidrosis, photosensitivity reaction, urticaria, pruritus, acne;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal, Connective Tissue, and Bone Disorders</content>: Muscle spasms, pain in extremity, myalgia, back pain;</paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive System and Breast Disorders</content>: Ovarian cyst, suppressed lactation, vulvovaginal dryness;</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions</content>: Chest pain, asthenic conditions.</paragraph>
                     </text>
                     <effectiveTime value="20250120"/>
                     <component>
                        <observationMedia ID="L1bb37679-579d-4429-815b-2bdb36d3dbfc">
                           <text>figure1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1060">
               <id root="67ffffcc-eefb-42ef-a549-b820dc42a4a0"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250120"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID1062">Drugs or herbal products that induce certain enzymes including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs. (<linkHtml href="#ID1065">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID1063">
                     <id root="37889885-817a-4ce2-8689-527c3ac97a37"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID1064">Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.</paragraph>
                        <paragraph>No drug-drug interaction studies were conducted with Mono-Linyah.</paragraph>
                     </text>
                     <effectiveTime value="20250120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1065">
                     <id root="147ce95d-8d48-4246-a851-abb5b9b6ac6d"/>
                     <title>7.1 Effects of Other Drugs on Combined Oral Contraceptives</title>
                     <text>
                        <paragraph ID="ID1066">
                           <content styleCode="underline">Substances decreasing the plasma concentrations of COCs</content>
                        </paragraph>
                        <paragraph>Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. Interactions between hormonal contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Colesevelam:</content> Colesevelam, a bile acid sequestrant, given together with a COC, has been shown to significantly decrease the AUC of EE. The drug interaction between the contraceptive and colesevelam was decreased when the two drug products were given 4 hours apart.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Substances increasing the plasma concentrations of COCs</content>
                        </paragraph>
                        <paragraph>Co-administration of atorvastatin or rosuvastatin and certain COCs containing ethinyl estradiol (EE) increase AUC values for EE by approximately 20-25%. Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Human immunodeficiency virus (HIV)/Hepatitis C virus (HCV) protease inhibitors, </content>
                           <content styleCode="underline">non-nucleoside reverse transcriptase inhibitors</content>
                           <content styleCode="underline">, and HIV/AIDS medications</content>
                           <br/>
                           <content styleCode="underline">containing strong inhibitors or inducers of CYP3A</content>
                        </paragraph>
                        <paragraph>Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of co-administration with HIV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir])/HCV protease inhibitors (decrease [e.g., boceprevir and telaprevir]) or with non-nucleoside reverse transcriptase inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]) or with HIV/AIDS medications containing strong inhibitors (e.g., cobicistat and ritonavir) or inducers of CYP3A.</paragraph>
                     </text>
                     <effectiveTime value="20241126"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1067">
                     <id root="6c6cea8b-7d93-49bf-85b4-4884205d68e2"/>
                     <title>7.2 Effects of Combined Oral Contraceptives on Other Drugs</title>
                     <text>
                        <list listType="unordered">
                           <item>COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations.</item>
                           <item>COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. Significant decrease in plasma concentration of lamotrigine has been shown, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary.</item>
                        </list>
                        <paragraph>Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because the serum concentration of thyroid-binding globulin increases with use of COCs.</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1069">
                     <id root="9f8c2410-d4f7-44b2-a274-2b439065cf40"/>
                     <title>7.3 Interactions with Laboratory Tests</title>
                     <text>
                        <paragraph ID="ID1070">The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins.</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1071">
                     <id root="1cf59efe-a765-46f6-9037-83fa5961f258"/>
                     <title>7.4 Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation</title>
                     <text>
                        <paragraph ID="ID1072">Do not co-administer Mono-Linyah with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID1020">5.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1073">
               <id root="3c9dfa31-97f1-48dc-9f33-d7162c3625d0"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250120"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Lactating women: Not recommended; can decrease milk production.<linkHtml href="#ID1078"> (8.2)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID1078">
                     <id root="967065c6-a5f6-490f-b023-3d5e749851dc"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID1079">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no use for contraception in pregnancy, therefore, Mono-Linyah should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to CHCs before conception or during early pregnancy.<br/>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20241126"/>
                  </section>
               </component>
               <component>
                  <section ID="L6419a68c-84d7-40fb-8d01-96311d1f4797">
                     <id root="f20a14a4-364c-4a3e-b4a8-97c3cbdf0d53"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Contraceptive hormones and/ or metabolites are present in human milk. CHCs can reduce milk production in breastfeeding females. This reduction can occur at any time but is less likely to occur once breastfeeding is well-established. When possible, advise the nursing female to use other forms of contraception until she discontinues breast-feeding. The developmental and health benfits of breast-feeding should be considered along with the mother's clinical need for Mono-Linyah and any potential adverse effects on the breast-fed child from Mono-Linyah or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1080">
                     <id root="3f29d75b-8374-40f3-891f-1b867fc88458"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID1081">Safety and efficacy of Mono-Linyah Tablets have been established in women of reproductive age. Efficacy is expected to be the same for post-pubertal adolescents under the age of 18 and for users 18 years and older. Use of this product before menarche is not indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1082">
                     <id root="11cb6d0d-e158-42a6-978e-ba3274c35cc3"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID1083">Mono-Linyah has not been studied in postmenopausal women and are not indicated in this population.</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1084">
                     <id root="ff86d76c-b0b4-4d15-b489-64391a424ff7"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID1085">The pharmacokinetics of Mono-Linyah has not been studied in subjects with hepatic impairment. However, steroid hormones may be poorly metabolized in patients with hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. <content styleCode="italics">[see Contraindications (</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID1007">4</linkHtml>
                           </content>
                           <content styleCode="italics">) and Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID1018">5.2</linkHtml>
                           </content>
                           <content styleCode="italics">).]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1086">
                     <id root="b3cfa2b8-deb8-4257-a6d8-6277a6d7a10b"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID1087">The pharmacokinetics of Mono-Linyah has not been studied in women with renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1088">
               <id root="7bc1642c-5a9e-4219-9f7a-6fdeaabe182c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID1089">There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.</paragraph>
               </text>
               <effectiveTime value="20250120"/>
            </section>
         </component>
         <component>
            <section ID="ID1090">
               <id root="3a1ae913-b2a0-4354-b96b-c1355a36befd"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID1091">Mono-Linyah is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)(+)-) and ethinyl estradiol is designated as (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol).</paragraph>
                  <list listType="unordered" ID="ID1092" styleCode="Disc">
                     <item>Each active blue tablet contains 0.250 mg of norgestimate and 0.035 mg of ethinyl estradiol. Inactive ingredients include: FD&amp;C Blue No. 2 Aluminium Lake, FD&amp;C Blue No. 1 Aluminum lake, FD&amp;C Red No. 40 Aluminum Lake, FD&amp;C Yellow No. 10 Aluminum Lake, titanium dioxide, polyvinyl alcohol, talc, macrogol/PEG 3350 NF, lecithin, lactose monohydrate, magnesium stearate and pregelatinized corn starch.</item>
                     <item>Each white placebo tablet containing only inert ingredients, as follows: titanium dioxide, polydextrose, hypromellose, triacetin, macrogol/polyethylene glycol, lactose monohydrate, magnesium stearate and pregelatinized corn starch.</item>
                  </list>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20240228"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1094">
               <id root="ddce6d34-5028-4b15-a0a9-32f12a6783d8"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250120"/>
               <component>
                  <section ID="ID1095">
                     <id root="7bd9f595-201b-40eb-8b15-f087dcadb617"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID1096">COCs lower the risk of becoming pregnant primarily by suppressing ovulation. </paragraph>
                     </text>
                     <effectiveTime value="20241126"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1097">
                     <id root="4a507f41-d7af-4f72-b338-c4ab3cc74d6f"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID1098">No specific pharmacodynamic studies were conducted with Mono-Linyah.</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1099">
                     <id root="3b886b5a-4617-4d5e-a7ca-4b072cfecdc4"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID1100">
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Norgestimate (NGM) and EE are rapidly absorbed following oral administration. NGM is rapidly and completely metabolized by first pass (intestinal and/or hepatic) mechanisms to norelgestromin (NGMN) and norgestrel (NG), which are the major active metabolites of norgestimate.</paragraph>
                        <paragraph>Peak serum concentrations of NGMN and EE are generally reached by 2 hours after administration of Mono-Linyah. Accumulation following multiple dosing of the 250 mcg NGM / 35 mcg EE dose is approximately 2-fold for NGMN and EE compared with single dose administration. The pharmacokinetics of NGMN is dose-proportional following NGM doses of 180 mcg to 250 mcg. Steady-state concentration of EE is achieved by Day 7 of each dosing cycle. Steady-state concentrations of NGMN and NG are achieved by Day 21. Non-linear accumulation (approximately 8 fold) of NG is observed as a result of high-affinity binding to SHBG, which limits its biological activity (Table 3).</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="L1fa82b4b-256a-41fa-910e-4aaeb6f943a6"/>
                        </paragraph>
                        <paragraph ID="ID1102">
                           <content styleCode="italics">Food Effect</content>
                        </paragraph>
                        <paragraph>The effect of food on the pharmacokinetics of Mono-Linyah has not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>NGMN and NG are highly bound (&gt;97%) to serum proteins. NGMN is bound to albumin and not to SHBG, while NG is bound primarily to SHBG. EE is extensively bound (&gt;97%) to serum albumin and induces an increase in the serum concentrations of SHBG.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>NGM is extensively metabolized by first-pass mechanisms in the gastrointestinal tract and/or liver. NGM's primary active metabolite is NGMN. Subsequent hepatic metabolism of NGMN occurs and metabolites include NG, which is also active, and various hydroxylated and conjugated metabolites. Although NGMN and its metabolites inhibit a variety of P450 enzymes in human liver microsomes, under the recommended dosing regimen, the <content styleCode="italics">in vivo</content> concentrations of NGMN and its metabolites, even at the peak serum levels, are relatively low compared to the inhibitory constant (Ki). EE is also metabolized to various hydroxylated products and their glucuronide and sulfate conjugates.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>The metabolites of NGMN and EE are eliminated by renal and fecal pathways. Following administration of <sup>14</sup>C-norgestimate, 47% (45-49%) and 37% (16-49%) of the administered radioactivity was eliminated in the urine and feces, respectively. Unchanged NGM was not detected in the urine. In addition to 17-deacetyl norgestimate, a number of metabolites of NGM have been identified in human urine following administration of radiolabeled NGM. These include 18, 19-Dinor-17-pregn-4-en-20-yn-3-one,17-hydroxy-13-ethyl,(17α)-(-);18,19-Dinor-5β-17-pregnan-20-yn,3α,17β-dihydroxy-13-ethyl,(17α), various hydroxylated metabolites and conjugates of these metabolites.</paragraph>
                     </text>
                     <effectiveTime value="20250120"/>
                     <component>
                        <observationMedia ID="L1fa82b4b-256a-41fa-910e-4aaeb6f943a6">
                           <text>table3</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="table3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1103">
               <id root="9506dca7-c9aa-40cd-b60c-f77ee37c8e31"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250120"/>
               <component>
                  <section ID="ID1104">
                     <id root="3125fe45-cc5e-419b-ab36-8b8f6be2599b"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID1105">
                           <content styleCode="italics">[See Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID1018">5.2</linkHtml>, <linkHtml href="#ID1036">5.10</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250120"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1106">
               <id root="ec209343-b054-49e2-8167-ad0d97657e30"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20240228"/>
               <component>
                  <section ID="ID1107">
                     <id root="d5235a11-d414-4da5-9c97-b1c56ddada01"/>
                     <title>14.1 Contraception</title>
                     <text>
                        <paragraph ID="ID1108">In three US clinical trials with norgestimate and ethinyl estradiol 0.25mg/0.035mg, 1,651 women aged 18 to 38 years were studied for up to 24 cycles, proving a total of 24,272 cycles of exposure. The racial demographic was about 73-86% Caucasian, 8-13% African-American, 6-14% Hispanic with the remainder Asian or Other (≤1%). There were no exclusions on the basis of weight; the weight range for women treated was 82-303 lbs, with a mean weight of about 135 lbs. The pregnancy rate was approximately 1 pregnancy per 100 women-years.</paragraph>
                     </text>
                     <effectiveTime value="20240228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1109">
               <id root="30bde710-a6f2-4d04-aecd-aa445803bdeb"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20241126"/>
               <component>
                  <section ID="ID1110">
                     <id root="154de9aa-2e47-470f-955e-d0e9fabf714f"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph ID="ID1111">Mono-Linyah Tablets are available in a compact blister card (NDC 16714-360-01) containing 28 tablets in the following order: 21 blue, biconvex, round, coated tablets with "C3" debossed on one side containing 0.250 mg norgestimate and 0.035 mg ethinyl estradiol, and 7 white, biconvex, round, coated tablets with "P" debossed on one side and the "<content styleCode="underline">N</content>" debossed on the other side containing inert ingredients.</paragraph>
                        <paragraph>Mono-Linyah Tablets are available in the following configurations:</paragraph>
                        <paragraph>Carton of 1 blister card NDC 16714-360-02</paragraph>
                        <paragraph>Carton of 3 blister cards NDC 16714-360-03</paragraph>
                        <paragraph>Carton of 6 blister cards NDC 16714-360-04</paragraph>
                     </text>
                     <effectiveTime value="20241126"/>
                  </section>
               </component>
               <component>
                  <section ID="ID1112">
                     <id root="e69d2d56-7dd0-4435-b2d5-03dce12330eb"/>
                     <title>16.2 Storage Conditions</title>
                     <text>
                        <list listType="unordered" ID="ID1113" styleCode="Disc">
                           <item>Store at 20° to 25℃ (68° to 77ºF);  excursions permitted to 15° to 30°C (59° to 86°F)<content styleCode="italics">.</content>
                           </item>
                           <item>Protect from light.</item>
                           <item>Keep out of the reach of children.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241126"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1114">
               <id root="721e829a-fe0d-4d34-84e1-31bcc435dd2d"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID1115">See FDA-approved Patient Labeling (Patient Information and Instructions for Use)<content styleCode="italics">. </content>Counsel patients about the following information:</paragraph>
                  <list listType="unordered" ID="ID1116" styleCode="Disc">
                     <item>Cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs<content styleCode="italics"> [see <linkHtml href="#ID972">Boxed Warning</linkHtml>]</content> .</item>
                     <item>Increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC<content styleCode="italics">[see Warnings and Precautions (</content>
                        <linkHtml href="#ID1016">5.1</linkHtml>
                        <content styleCode="italics">)]</content> .</item>
                     <item>Mono-Linyah does not protect against HIV infection (AIDS) and other sexually transmitted infections.</item>
                     <item>Mono-Linyah is not to be used during pregnancy; if pregnancy occurs during use of Mono-Linyah instruct the patient to stop further use<content styleCode="italics">[</content>
                        <content styleCode="italics">see Use in Specific Populations (8.1)]</content> .</item>
                     <item>Take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event tablets are missed<content styleCode="italics">[see Dosage and Administration (</content>
                        <linkHtml href="#ID987">2.1,2.2</linkHtml>
                        <content styleCode="italics">)]</content> .</item>
                     <item>Use a back-up or alternative method of contraception when enzyme inducers are used with Mono-Linyah<content styleCode="italics"> [see Drug Interactions (</content>
                        <linkHtml href="#ID1065">7.1</linkHtml>
                        <content styleCode="italics">)]</content> .</item>
                     <item>COCs may reduce breast milk production; this is less likely to occur if breastfeeding is well established<content styleCode="italics">[see Use in Specific Populations (</content>
                        <linkHtml href="#ID1078">8.2</linkHtml>
                        <content styleCode="italics">)]</content> .</item>
                     <item>Women who start COCs postpartum, and who have not yet had a period, should use an additional method of contraception until they have taken an active tablet for 7 consecutive days<content styleCode="italics"> [see Dosage and Administration (</content>
                        <linkHtml href="#ID987">2.1</linkHtml>
                        <content styleCode="italics">)]</content> .</item>
                     <item>Amenorrhea may occur. Consider pregnancy in the event of amenorrhea at the time of the first missed period. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles<content styleCode="italics"> [see Warnings and Precautions (</content>
                        <linkHtml href="#ID1030">5.8</linkHtml>
                        <content styleCode="italics">)].</content>
                     </item>
                  </list>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph ID="ID1118">Revised: Jan 2025                                             I0020 Rev. F</paragraph>
               </text>
               <effectiveTime value="20250120"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>5</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1119">
               <id root="186c1cf0-251b-453f-b644-61a6eb83dcc7"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <paragraph ID="ID1120">
                     <content styleCode="bold">Patient Information</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Mono-Linyah[Mon-oh-lin-YAH]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(norgestimate and ethinyl estradiol) Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about Mono-Linyah?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not use Mono-Linyah if you smoke cigarettes and are over 35 years old. </content>Smoking increases your risk of serious cardiovascular side effects from hormonal birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is Mono-Linyah?</content>
                  </paragraph>
                  <paragraph>Mono-Linyah is a birth control pill (oral contraceptive) used by women to prevent pregnancy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How does Mono-Linyah work for contraception?</content>
                  </paragraph>
                  <paragraph>Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant.</paragraph>
                  <paragraph>Based on the results of clinical studies, about 1 out of 100 women may get pregnant during the first year they use Mono-Linyah.</paragraph>
                  <paragraph>The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Ld5810768-577c-4209-a7b4-1e8c44a186c9"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take MONO-LINYAH? Do not take MONO-LINYAH if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1123" styleCode="Disc">
                     <item>smoke and are over 35 years of age</item>
                     <item>had blood clots in your arms, legs, lungs, or eyes</item>
                     <item>had a problem with your blood that makes it clot more than normal</item>
                     <item>have certain heart valve problems or irregular heart beat that increases your risk of having blood clots</item>
                     <item>had a stroke</item>
                     <item>had a heart attack</item>
                     <item>have high blood pressure that cannot be controlled by medicine</item>
                     <item>have diabetes with kidney, eye, nerve, or blood vessel damage</item>
                     <item>have certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or any migraine headaches if you are over 35 years of age</item>
                     <item>have liver problems, including liver tumors</item>
                     <item>take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme "alanine aminotransferase" (ALT) in the blood.</item>
                     <item>have any unexplained vaginal bleeding</item>
                     <item>are pregnant</item>
                     <item>had breast cancer</item>
                  </list>
                  <paragraph ID="ID1124">
                     <content styleCode="bold">If any of these conditions happen while you are taking MONO-LINYAH, stop taking MONO-LINYAH right away and talk to your healthcare provider. Use non-hormonal contraception when you stop taking MONO-LINYAH.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my healthcare provider before taking MONO-LINYAH?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1125" styleCode="Disc">
                     <item>are pregnant or think you may be pregnant</item>
                     <item>are depressed now or have been depressed in the past</item>
                     <item>had yellowing of your skin or eyes (jaundice) caused by pregnancy (cholestasis of pregnancy)</item>
                     <item>are breastfeeding or plan to breastfeed.MONO-LINYAH may decrease the amount of breast milk you make. A small amount of the hormones in MONO-LINYAH may pass into your breast milk. Talk to your healthcare provider about the best birth control method for you while breastfeeding.</item>
                  </list>
                  <paragraph ID="ID1126">
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take, </content>including prescription and over-the-counter medicines, vitamins and herbal supplements.</paragraph>
                  <paragraph>MONO-LINYAH may affect the way other medicines work, and other medicines may affect how well MONO-LINYAH works.</paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take MONO-LINYAH?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read the</content>
                     <content styleCode="bold"> Instructions for Use </content>at the end of this Patient Information<content styleCode="bold">.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible serious side effects of MONO-LINYAH?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1127" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Like pregnancy, MONO-LINYAH may cause serious side effects, including blood clots in your lungs, heart attack, or a stroke that may lead to death. Some other examples of serious blood clots include blood clots in the legs or eyes.</content>
                     </item>
                  </list>
                  <paragraph>Serious blood clots can happen especially if you smoke, are obese, or are older than 35 years of age. Serious blood clots are more likely to happen when you:</paragraph>
                  <list listType="unordered" ID="ID1129" styleCode="Disc">
                     <item>first start taking birth control pills</item>
                     <item>restart the same or different birth control pills after not using them for a month or more</item>
                  </list>
                  <paragraph ID="ID1130">
                     <content styleCode="bold">Call your healthcare provider or go to a hospital emergency room right away if you have:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1131" styleCode="Disc">
                     <item>leg pain that will not go away</item>
                     <item>sudden severe shortness of breath</item>
                     <item>sudden change in vision or blindness</item>
                     <item>chest pain</item>
                     <item>a sudden, severe headache unlike your usual headaches</item>
                     <item>weakness or numbness in your arm or leg</item>
                     <item>trouble speaking</item>
                  </list>
                  <paragraph ID="ID1132">
                     <content styleCode="bold">Other serious side effects include:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1133" styleCode="Disc">
                     <item>
                        <content styleCode="bold">liver problems, including:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>rare liver tumors</item>
                           <item>jaundice (cholestasis), especially if you previously had cholestasis of pregnancy. Call your healthcare provider if you have yellowing of your skin or eyes.</item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">high blood pressure.</content> You should see your healthcare provider for a yearly check of your blood pressure.</item>
                     <item>
                        <content styleCode="bold">gallbladder problems</content>
                     </item>
                     <item>
                        <content styleCode="bold">changes in the sugar and fat (cholesterol and triglycerides) levels in your blood</content>
                     </item>
                     <item>
                        <content styleCode="bold">new or worsening headaches including migraine headaches</content>
                     </item>
                     <item>
                        <content styleCode="bold">irregular or unusual vaginal bleeding and spotting between your menstrual periods, especially during the first 3 months of taking MONO-LINYAH.</content>
                     </item>
                     <item>
                        <content styleCode="bold">depression</content>
                     </item>
                     <item>
                        <content styleCode="bold">possible cancer in your breast and cervix</content>
                     </item>
                     <item>
                        <content styleCode="bold">severe allergic reactions that may include swelling of your skin especially around your mouth, eyes, and in your throat (angioedema).</content> Call your healthcare provider if you have a swollen face, lips, mouth tongue or throat, which may lead to difficulty swallowing or breathing. Your chance of having angioedema is higher is you have a history of angioedema.</item>
                     <item>
                        <content styleCode="bold">dark patches of skin around your forehead, nose, cheeks and around your mouth, especially during pregnancy (chloasma).</content> Women who tend to get chloasma should avoid spending a long time in sunlight, tanning booths, and under sun lamps while taking MONO-LINYAH. Use sunscreen if you have to be in the sunlight.</item>
                  </list>
                  <paragraph ID="ID1134">
                     <content styleCode="bold">What are the most common side effects of MONO-LINYAH?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1135" styleCode="Disc">
                     <item>headache (migraine)</item>
                     <item>breast pain or tenderness, enlargement or discharge</item>
                     <item>stomach pain, discomfort, and gas</item>
                     <item>vaginal infections and discharge</item>
                     <item>mood changes, including depression</item>
                     <item>nervousness</item>
                     <item>changes in weight</item>
                     <item>skin rash</item>
                  </list>
                  <paragraph ID="ID1136">These are not all the possible side effects of MONO-LINYAH. For more information, ask your healthcare provider or pharmacist.</paragraph>
                  <paragraph>You may report side effects to the FDA at 1-800-FDA-1088<content styleCode="bold">.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What else should I know about taking MONO-LINYAH?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1137" styleCode="Disc">
                     <item>If you are scheduled for any lab tests, tell your healthcare provider you are taking MONO-LINYAH. Certain blood tests may be affected by MONO-LINYAH.</item>
                     <item>MONO-LINYAH does not protect against HIV infection (AIDS) and other sexually transmitted infections.</item>
                  </list>
                  <paragraph ID="ID1138">
                     <content styleCode="bold">How should I store MONO-LINYAH?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1139" styleCode="Disc">
                     <item>Store MONO-LINYAH at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                     <item>Keep MONO-LINYAH and all medicines out of the reach of children.</item>
                     <item>Store away from light.</item>
                  </list>
                  <paragraph ID="ID1140">
                     <content styleCode="bold">General information about the safe and effective use of MONO-LINYAH.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.</paragraph>
                  <paragraph>Do not use MONO-LINYAH for a condition for which it was not prescribed. Do not give MONO-LINYAH to other people, even if they have the same symptoms that you have.</paragraph>
                  <paragraph>This Patient Information summarizes the most important information about MONO-LINYAH. You can ask your pharmacist or healthcare provider for information about MONO-LINYAH that is written for health professionals<content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>For more information, call 1-800-206-7821.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Does birth control cause cancer?</content>
                  </paragraph>
                  <paragraph>It is not known if hormonal birth control pills causes breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use.</paragraph>
                  <paragraph>If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones.</paragraph>
                  <paragraph>Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if I want to become pregnant?</content>
                  </paragraph>
                  <paragraph>You may stop taking the pill whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the pill.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I know about my period when taking MONO-LINYAH?</content>
                  </paragraph>
                  <paragraph>Your periods may be lighter and shorter than usual. Some women may miss a period. Irregular vaginal bleeding or spotting may happen while you are taking MONO-LINYAH, especially during the first few months of use. This usually is not a serious problem. It is important to continue taking your pills on a regular schedule to prevent a pregnancy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in MONO-LINYAH? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredients:</content>
                  </paragraph>
                  <paragraph>Each blue pill contains norgestimate and ethinyl estradiol.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content>
                  </paragraph>
                  <paragraph>Blue pills: FD&amp;C Blue No. 2 Aluminium Lake, FD&amp;C Blue No. 1 Aluminum lake, FD&amp;C Red No. 40 Aluminum Lake, FD&amp;C Yellow No. 10 Aluminum Lake, titanium dioxide, polyvinyl alcohol, talc, macrogol/PEG 3350 NF, lecithin, lactose monohydrate, magnesium stearate and pregelatinized corn starch</paragraph>
                  <paragraph>White pills: titanium dioxide, polydextrose, hypromellose, triacetin, macrogol/polyethylene glycol, lactose monohydrate, magnesium stearate and pregelatinized corn starch.</paragraph>
               </text>
               <effectiveTime value="20250120"/>
               <component>
                  <observationMedia ID="Ld5810768-577c-4209-a7b4-1e8c44a186c9">
                     <text>6</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID1141">
               <id root="6ea9783d-7b11-4681-8e26-62bdcef40f5b"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID1142">
                     <content styleCode="bold">Instructions For Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Mono-Linyah [Mon-oh-lin-YAH]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> (norgestimate and ethinyl estradiol) Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Information about taking MONO-LINYAH</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1143" styleCode="Disc">
                     <item>Take <content styleCode="bold">1</content> pill every day at the same time. Take the pills in the order directed on your pill dispenser.</item>
                     <item>Do not skip your pills, even if you do not have sex often. If you miss pills (including starting the pack late) <content styleCode="bold">you could get pregnant</content>. The more pills you miss, the more likely you are to get pregnant.</item>
                     <item>If you have trouble remembering to take MONO-LINYAH, talk to your healthcare provider. When you first start taking MONO-LINYAH, spotting or light bleeding in between your periods may occur. Contact your healthcare provider if this does not go away after a few months.</item>
                     <item>You may feel sick to your stomach (nauseous), especially during the first few months of taking MONO-LINYAH. If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If your nausea does not go away, call your healthcare provider.</item>
                     <item>Missing pills can also cause spotting or light bleeding, even when you take the missed pills later. On the days you take 2 pills to make up for missed pills (see <content styleCode="bold">What should I do if I miss any MONO-LINYAH pills?</content> below), you could also feel a little sick to your stomach.</item>
                     <item>It is not uncommon to miss a period. However, if you miss a period and have not taken MONO-LINYAH according to directions, or miss <content styleCode="bold">2</content> periods in a row, or feel like you may be pregnant, call your healthcare provider. If you have a positive pregnancy test, you should stop taking MONO-LINYAH.</item>
                     <item>If you have vomiting or diarrhea within <content styleCode="bold">3-4</content> hours of taking your pill, take another pill of the same color from your extra pill dispenser. If you do not have an extra pill dispenser, take the next pill in your pill dispenser. Continue taking all your remaining pills in order. Start the first pill of your next pill dispenser the day after finishing your current pill dispenser. This will be 1 day earlier than originally scheduled. Continue on your new schedule.</item>
                     <item>If you have vomiting or diarrhea for more than 1 day, your birth control pills may not work as well. Use an additional birth control method, like condoms and a spermicide, until you check with your healthcare provider.</item>
                     <item>Stop taking MONO-LINYAH at least <content styleCode="bold">4</content> weeks before you have major surgery and do not restart after the surgery without asking your healthcare provider. Be sure to use other forms of contraception (like condoms and spermicide) during this time period.</item>
                  </list>
                  <paragraph ID="ID1144">
                     <content styleCode="bold">Before you start taking MONO-LINYAH:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1145" styleCode="Disc">
                     <item>Decide what time of day you want to take your pill. It is important to take it at the same time every day and in the order as shown on your compact blister card.</item>
                     <item>Have backup contraception (condoms and spermicide) available and if possible, an extra full pack of pills as needed.</item>
                  </list>
                  <paragraph ID="ID1146">
                     <content styleCode="bold">When should I start taking MONO-LINYAH?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you start taking MONO-LINYAH and you have not used a hormonal birth control method before:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1147" styleCode="Disc">
                     <item>There are 2 ways to start taking your birth control pills. You can either start on a Sunday (Sunday Start) or on the first day (Day 1) of your natural menstrual period (Day 1 Start). Your healthcare provider should tell you when to start taking your birth control pill.</item>
                     <item>If you use the Sunday Start, use non-hormonal back-up contraception such as condoms and spermicide for the first <content styleCode="bold">7</content> days that you take MONO-LINYAH. You do not need back-up contraception if you use the Day 1 Start.</item>
                  </list>
                  <paragraph ID="ID1148">
                     <content styleCode="bold">If you start taking MONO-LINYAH and you are switching from another birth control pill:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1149" styleCode="Disc">
                     <item>Start your new MONO-LINYAH pack on the same day that you would start the next pack of your previous birth control method.</item>
                     <item>Do not continue taking the pills from your previous birth control pack.</item>
                  </list>
                  <paragraph ID="ID1150">
                     <content styleCode="bold">If you start taking MONO-LINYAH and previously used a vaginal ring or transdermal patch:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1151" styleCode="Disc">
                     <item>Start using MONO-LINYAH on the day you would have reapplied the next ring or patch.</item>
                  </list>
                  <paragraph ID="ID1152">
                     <content styleCode="bold">If you start taking MONO-LINYAH and you are switching from a progestin-only method such as an implant or injection:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1153" styleCode="Disc">
                     <item>Start taking MONO-LINYAH on the day of removal of your implant or on the day when you would have had your next injection.</item>
                  </list>
                  <paragraph ID="ID1154">
                     <content styleCode="bold">If you start taking MONO-LINYAH and you are switching from an intrauterine device or system (IUD or IUS):</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1155" styleCode="Disc">
                     <item>Start taking MONO-LINYAH on the day of removal of your IUD or IUS.</item>
                     <item>You do not need back-up contraception if your IUD or IUS is removed on the first day (Day 1) of your period. If your IUD or IUS is removed on any other day, use non-hormonal back-up contraception such as condoms and spermicide for the first <content styleCode="bold">7</content> days that you take MONO-LINYAH.</item>
                  </list>
                  <paragraph ID="ID1156">
                     <content styleCode="bold">Keep a calendar to track your period:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If this is the first time </content>you are taking birth control pills, read, "<content styleCode="bold">When should I start taking MONO-LINYAH?</content>" above.</paragraph>
                  <paragraph>MONO-LINYAH is available as a blister card placed within a white compact with the days of the week imprinted on the white compact preset for a Sunday start. The MONO-LINYAH blister card has 21 blue "active" pills (with hormones) to take for 3 weeks. This is followed by 1 week of 7 white "reminder" pills (without hormones). The MONO-LINYAH blister card and the imprinted days of the week on the compact is shown in the picture below.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Leeef3774-47a0-4e49-92f7-d901c306f6b9"/>
                  </paragraph>
                  <paragraph>
                     <content>On the above blister card find where on the card to start taking pills, in what order to take the pills and the week numbers. Day 1 stickers are also provided.</content>
                  </paragraph>
                  <paragraph>Follow these instructions for either a <content styleCode="bold">Sunday Start </content>or a <content styleCode="bold">Day 1 Start</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sunday Start:</content>
                  </paragraph>
                  <paragraph>You will use a <content styleCode="bold">Sunday Start </content>if your healthcare provider told you to take your first pill on a Sunday.</paragraph>
                  <list listType="unordered" ID="ID1159" styleCode="Disc">
                     <item>Take pill <content styleCode="bold">1</content> on the Sunday <content styleCode="bold">after your period starts.</content>
                     </item>
                     <item>If your period starts on a Sunday, take pill "<content styleCode="bold">1</content> " that day and refer to Day 1 Start instructions below.</item>
                     <item>Take <content styleCode="bold">1</content> pill every day in the order on the blister card at the same time each day for <content styleCode="bold">28</content> days.</item>
                     <item>After taking the last pill on <content styleCode="bold">Day 28</content> from the blister card, start taking the first pill from a new pack, on the same day of the week as the first pack (Sunday). Take the first pill in the new pack whether or not you are having your period.</item>
                     <item>Use non-hormonal back-up contraception such as condoms and spermicide for the first <content styleCode="bold">7</content> days of the first cycle that you take MONO-LINYAH.</item>
                  </list>
                  <paragraph ID="ID1160">
                     <content styleCode="bold">Day 1 Start:</content>
                  </paragraph>
                  <paragraph>You will use a <content styleCode="bold">Day 1 Start </content>if your doctor told you to take your first pill (Day 1) on the <content styleCode="bold">first day of your period</content>. Refer to Day 1 Start instructions below.</paragraph>
                  <paragraph>1. Pick the day label sticker that starts with the first day of your period.</paragraph>
                  <paragraph>2. Place this day label sticker over the area on the plastic compact which already has the days of the week (starting with Sunday) imprinted and press firmly. See the picture below as an example.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L568e2636-9ca0-4d2e-acd3-3ea867c766bc"/>
                  </paragraph>
                  <list listType="unordered" ID="ID1162" styleCode="Disc">
                     <item>Take <content styleCode="bold">1</content> pill every day in the order on the blister card, at the same time each day for <content styleCode="bold">28</content> days.</item>
                     <item>After taking the last pill on <content styleCode="bold">Day 28</content> from the blister card, start taking the first pill from a new pack, on the same day of the week as the first pack. Take the first pill in the new pack whether or not you are having your period.</item>
                  </list>
                  <paragraph ID="ID1163">
                     <content styleCode="bold">What should I do if I miss any MONO-LINYAH pills?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you miss 1 pill in Weeks 1, 2, or 3, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1164" styleCode="Disc">
                     <item>Take it as soon as you remember. Take the next pill at your regular time. This means you may take <content styleCode="bold">2</content> pills in <content styleCode="bold">1</content> day.</item>
                     <item>Then continue taking <content styleCode="bold">1</content> pill every day until you finish the pack.</item>
                     <item>You do not need to use a back-up birth control method if you have sex.</item>
                  </list>
                  <paragraph ID="ID1165">
                     <content styleCode="bold">If you miss 2 pills in Week 1 or Week 2 of your pack, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1166" styleCode="Disc">
                     <item>Take the 2 missed pills as soon as possible and the next 2 pills the next day.</item>
                     <item>Then continue to take <content styleCode="bold">1</content> pill every day until you finish the pack.</item>
                     <item>Use a non-hormonal birth control method (such as a condom and spermicide) as a back-up if you have sex during the first <content styleCode="bold">7 days</content> after missing your pills.</item>
                  </list>
                  <paragraph ID="ID1167">
                     <content styleCode="bold">If you miss 2 pills in a row in Week 3, or you miss 3 or more pills in a row during Weeks 1, 2, or 3 of the pack, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID1168" styleCode="Disc">
                     <item>
                        <content styleCode="bold">If you are a Day 1 Starter:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>Throw out the rest of the pill pack and start a new pack that same day.</item>
                           <item>You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your healthcare provider because you might be pregnant.</item>
                           <item>You could become pregnant if you have sex during the first 7 days after you restart your pills. You MUST use a non-hormonal birth control method (such as a condom and spermicide) as a back-up if you have sex during the first <content styleCode="bold">7</content> days after you restart your pills.</item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">If you are a Sunday Starter:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>Keep taking <content styleCode="bold">1</content> pill every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of pills that same day.</item>
                           <item>Use a non-hormonal birth control method (such as a condom and spermicide) as a back-up if you have sex during the first <content styleCode="bold">7</content> days after you restart your pills.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph ID="ID1169">
                     <content styleCode="bold">If you have any questions or are unsure about the information in this leaflet, call your healthcare provider.</content>
                  </paragraph>
                  <paragraph>
                     <content>
                        <renderMultiMedia referencedObject="Lafb28dae-b577-4168-93bc-6a28688b9d1c"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>Manufactured for: Northstar Rx LLC</content>
                  </paragraph>
                  <paragraph>Memphis TN 38141</paragraph>
                  <paragraph/>
                  <paragraph>Manufactured by: Novast Laboratories Ltd.</paragraph>
                  <paragraph>Nantong, China 226009</paragraph>
                  <paragraph>Revised: Jan 2025                                   I0020 Rev. F</paragraph>
               </text>
               <effectiveTime value="20250120"/>
               <component>
                  <observationMedia ID="Leeef3774-47a0-4e49-92f7-d901c306f6b9">
                     <text>7</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L568e2636-9ca0-4d2e-acd3-3ea867c766bc">
                     <text>8</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lafb28dae-b577-4168-93bc-6a28688b9d1c">
                     <text>9</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L1c1898ca-7d7d-462e-8a61-1445114bee78">
               <id root="60f41551-07ef-47f7-ae19-d928398373c4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lb9a95152-5b8e-4991-8a36-c25dc2ba79e4"/>
                  </paragraph>
                  <paragraph>Add image transcription here...</paragraph>
               </text>
               <effectiveTime value="20240228"/>
               <component>
                  <observationMedia ID="Lb9a95152-5b8e-4991-8a36-c25dc2ba79e4">
                     <text>10</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>